Cincinnati Enquirer: UC College of Medicine launches addiction research center
The center is devoted to the science of addiction and hopes to help end stigma
A research center devoted to the science of addiction and determined to make a national impact has launched at the University of Cincinnati College of Medicine.
The UC Center for Addiction Research is an endeavor "to expand the university’s scope as a national leader in addiction science," officials said.
The center's director is Theresa Winhusen, PhD, vice chair for addiction sciences in the Psychiatry and Behavioral Neurosciences department at the UC College of Medicine.
"This is a chance to take all the work that we've been doing to the next level," says Winhusen, who's been engaged in addiction research for more than 20 years.
Read the full story. [This article is password protected.]
Featured photo of Andrew Norman, PhD, a leader of one of the cores of the Center for Addiction Research, in his lab. Photo credit/Colleen Kelley/UC Creative + Brand
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.